1. Introduction {#sec1}
===============

The IL-1 pathway plays a plays a critical role in the regulation of immune and inflammatory responses to infections and sterile insults \[[@B1]\]. IL-1 signaling is also frequently upregulated in many solid tumor types including head and neck squamous cell carcinomas (HNSCCs) \[[@B2]\]. Although increased IL-1 signaling is typically associated with poor prognosis in cancer patients \[[@B3]--[@B5]\], the role of IL-1 signaling in cancer is controversial since IL-1 plays roles in both tumor promotion via the expression of genes involved in tumor survival, angiogenesis, metastasis, and immune cell recruitment \[[@B6]--[@B8]\] and tumor suppression via increased natural killer (NK) cell activity and enhanced Th1-mediated immunity \[[@B9], [@B10]\].

The IL-1 pathway is triggered when the ligands IL-1*α* and IL-1*β* bind to IL-1 receptor type I (IL-1R1). Upon ligand binding, the receptor forms a heterodimer with IL-1 receptor accessory protein (IL-1RAcP), which leads to the recruitment of the cytosolic coadaptor protein myeloid differentiation primary response gene 88 (MyD88) via its toll-like-interleukin-1 receptor (TIR) domain, followed by recruitment of IL-1 receptor-associated kinases and TNF Receptor Associated Factor 6 (TRAF6) \[[@B11]\]. These signaling events activate nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) and mitogen-activated protein kinases (MAPK) signaling leading to the expression of IL-1 target genes including activating IL-1 ligands (IL-1*α* and IL-1*β*) which activate and reinforce a positive feed-forward loop and sustained release of cytokines \[[@B11]\].

Of the activating ligands in the IL-1 family, IL-1*β* is the most studied. IL-1*β* is initially translated into an immature pro-IL-1*β* and cleaved into its active form by caspase-1 and released from the cell \[[@B11]\]. IL-1*α* is less studied and has a different biological role than IL-1*β*. IL-1*α* also exists as a precursor (pro-IL-1*α*) and can be cleaved by the calcium-activated neutral protease calpain into a 17-kDa C-terminal component, known as "mature" IL-1*α*, and a 16-kDa N-terminal propiece (ppIL-1*α*) \[[@B12]\]. Both pro-IL-1*α* and the mature IL-1*α* are active and are able to bind to IL-1R1 and trigger signaling \[[@B12]\]. Pro-IL-1*α* also contains a nuclear localization signal (NLS) not present in the mature form, which is retained in the ppIL-1*α* after cleavage of pro-IL-1*α* \[[@B13]\]. This allows both pro-IL-1*α* and ppIL-*α* to translocate to the nucleus. Nuclear localization of IL-1*α* (i.e., pro-IL-1*α* and ppIL-1*α*) is believed to be functionally important, due to the ability of these entities to bind DNA \[[@B14]\] and activate NFkB and specificity protein 1 (Sp1) which play important roles in cell proliferation \[[@B15]\].

Previous work has shown that HNSCC tumors have increased mRNA expression levels of IL-1*α* and IL-1*β* compared to adjacent normal tissue \[[@B6]\] and that tumors with high IL-1*α* gene expression and protein secretion are associated with the development of distant metastasis in HNSCC patients \[[@B5]\]. Despite these previous observations, little is known about the*in situ* tumor expression of IL-1*α* in HNSCCs, the subcellular distribution of IL-1*α* in HNSCC tumors, and the prognostic significance of IL-1*α* localization in HNSCC patients. Additionally, EGFR is well known as a prognostic marker in HNSCC \[[@B16]\] and a crosstalk relationship has been previously reported between the EGFR and IL-1 pathways \[[@B17], [@B18]\]. The goals of this study are to (1) characterize the subcellular distribution of IL-1*α* in OSCCs and (2) determine the prognostic significance of IL-1*α* subcellular localization and combined EGFR/IL-1*α* expression in OSCC patients.

2. Materials and Methods {#sec2}
========================

2.1. Tissue Microarrays (TMAs) {#sec2.1}
------------------------------

Formalin-fixed paraffin-embedded tumor samples of patients were obtained from the archives of the Department of Pathology at the University of Iowa Hospitals and Clinics. TMAs were constructed using 3-6 morphologically representative tumor regions (1 mm) chosen from 146 carcinomas from the oral cavity. The 146 cases were surgical resection specimens and chosen selectively to ensure a mixture of patients with and without recurrence, with and without node metastases or positive margins, young and old ages, and smokers and nonsmokers from a population of 421 patients spanning 10 years of time (2005-2014). After generating a list of 266 patients proposed for inclusion in the TMA, only 146 were included in the TMA block construction due to paraffin-embedded formalin-fixed tissue block availability and quality and resource constraints. Chi-square analysis of the T stage distribution of the patients in the larger database (T1/T2/T3&4: 31/29/39%) showed no statistically significant difference from the patient cohort included in the study (29/29/40%). None of the patients included in the TMA underwent prior radiation or chemotherapy. Four *μ*m sections were obtained from the TMAs on poly-L-lysine-coated glass slides. Routine hematoxylin and eosin (H&E) sections were reviewed to confirm the original diagnosis.

2.2. Immunohistochemistry (IHC) {#sec2.2}
-------------------------------

Antigen retrieval was performed on freshly cut sections in a decloaking chamber for 5 min at 125°C in TRIS buffer (pH 9.0). Endogenous peroxidase was blocked by incubation with 3% peroxide at room temperature for 2 min. For IL-1*α* staining, human specific IL-1*α* antibody (ab9614, Abcam) was applied at 1:250 in Dako diluent for 2 h at room temperature. The peptide sequence used to raise this antibody is SAPFSFLSNVKYNFMRIIKYEFILNDALNQSIIRANDQYLTAAALHNLDEAVKFDMGAYKSSKDDAKITVILRISKTQLYVTAQDEDQPVLLKEMPEIPKTITGSETNLLFFWETHGTKNYFTSVAHPNLFIATKQDYWVCLAGGPPSITDFQILENQA (amino acids 113-271) and therefore recognizes both full length/pro-IL-1*α* (amino acids 1-271) and mature IL-1*α* (amino acids 113-271). EGFR immunostaining was performed with antibody (H11, Dako) at 1:200 dilution. Bound antibody was detected using Envison™ + HRP, rabbit (Dako North America) for 30 min at room temperature followed by incubation with diaminobenzidine substrate (DAB) for 5 min at room temperature. HPV status was determined by p16 expression \[[@B19], [@B20]\]. After completion of IHC, slides were stored at room temperature and a virtual scanned copy of the TMA slides was kept for further reference.

2.3. Quantification of IL-1*α* and EGFR Staining {#sec2.3}
------------------------------------------------

IL-1*α* immunoreactivity was evaluated by KGC using an Olympus BX53 microscope with an Olympus DP72 camera. Human kidney and spleen were used as positive and negative controls for IL-1*α* expression, respectively. Given that IL-1*α* expression varied in both the nuclei and cytoplasm, IL-1*α* expression was scored separately for the nuclei (N) and cytoplasm (C) on a scale from 0 to 2, with 0 representing no staining, 1 low/weak staining, and 2 strong/intense staining. The percentage of tumor cells with positive staining was determined by scoring 10 microscopic fields of 100 tumor cells each. Quantitative evaluation of EGFR staining was performed by AR according to Gamboa-Domingez et al. and Modern Pathology, 2004 \[[@B21]\], using a semiquantitative score (0-3+) where 0 represents no staining or membranous positivity in \<10% neoplastic cells (negative) and 1, 2, and 3 represent weak, moderate, and strong membranous immunopositivity in \>10% neoplastic cells.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The associations between IL-1*α* and/or EGFR expression with clinicopathological features such as sex, age, smoking history, tumor site, pathological TNM classification (UICC 7th), differentiation (well/moderately/poor), perineural, lymphovascular, and bone invasion were tested using the generalized linear modeling (GLM) framework and the Kruskal-Wallis test. Differences in survival outcomes (overall survival \[OS\] and progression-free survival \[PFS\]) were plotted using the Kaplan-Meier method while estimates for the group hazard ratios were obtained using Cox proportional hazards (PH) modeling. OS is defined as the length of time from the date of diagnosis that the patients remain alive. PFS is defined as the time from diagnosis to disease progression or death from any cause. All testing was performed on the univariate level and unadjusted for multiple comparisons. Differences between survival curves were compared using the log-rank test. A*p*-value below 0.05 was considered statistically significant. All analyses were completed using SAS 9.4.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

A total of 146 patient samples were included in the OSCC TMA, of which 141 showed interpretable IL-1*α* and EGFR immunostaining. Reasons for lost samples included loss/absence of tissue in the TMA section during IHC processing. The baseline characteristics for these patients are summarized in [Table 1](#tab1){ref-type="table"}. Of the 141 patients, 82 patients were males with an average age of diagnosis of 58 years, and 59 patients were female with an average age of diagnosis of 66 years ([Table 1](#tab1){ref-type="table"}). Smoking histories were reported in most patients with 56 (40%) active smokers, 13 (9%) that had quit smoking for less than 10 years, 17 (12%) that quit smoking for more than 10 years, and 6 (4.3%) tobacco chewers ([Table 1](#tab1){ref-type="table"}). Males made up the majority (78%) of the active smokers and females made up the majority of the patients with no smoking history (68%, (data not shown)). Majority of tumor sites represented in the TMA were from the oral tongue, N0 (52%), and moderately differentiated (64%) ([Table 1](#tab1){ref-type="table"}). Approximately 78 (55%) patients received adjuvant radiotherapy and 22 (16%) patients received chemotherapy following surgery ([Table 1](#tab1){ref-type="table"}). Only 5 of the evaluable tumors were HPV-positive as detected by p16 expression (data not shown).

3.2. IL-1*α* Expression {#sec3.2}
-----------------------

IL-1*α* expression was detected in the cytoplasm and/or nucleus in at least 1 of 3-6 cores for the vast majority of patients (98%). Examples of IHC images of primarily nuclear, primarily cytoplasmic and combined nuclear/cytoplasmic IL-1*α* immunoreactivity are shown in Figures [1(a)](#fig1){ref-type="fig"}--[1(c)](#fig1){ref-type="fig"}, respectively. Combined nuclear/cytoplasmic IL-1*α* scores were generated for each patient based on the intensity (negative \[0\], moderate \[1\], and strong \[2\]) of IL-1*α* staining in each compartment. Tumors were assigned IL-1*α* nuclear/cytoplasmic (N/C) expression profile scores including 0/0: negative nuclear and cytoplasmic IL-1*α* expression ([Figure 1(d)](#fig1){ref-type="fig"}); 1/0: moderate nuclear and negative cytoplasmic IL-1*α* expression ([Figure 1(e)](#fig1){ref-type="fig"}); 0/1: negative nuclear and moderate cytoplasmic IL-1*α* expression ([Figure 1(f)](#fig1){ref-type="fig"}); 1/1: moderate nuclear and cytoplasmic IL-1*α* expression ([Figure 1(g)](#fig1){ref-type="fig"}); 1/2: moderate nuclear and strong cytoplasmic IL-1*α* expression ([Figure 1(h)](#fig1){ref-type="fig"}); and 2/1: strong nuclear and moderate cytoplasmic IL-1*α* expression ([Figure 1(i)](#fig1){ref-type="fig"}). An IL-1*α* expression profile of 1/1 represented the majority (n=81, \[58%\]) of tumors in the TMA ([Table 2](#tab2){ref-type="table"}).

3.3. Correlation of IL-1*α* Expression with Clinicopathologic Parameters {#sec3.3}
------------------------------------------------------------------------

There were no differences in nuclear or cytoplasmic IL-1*α* expression scores based on sex or age ([Table 1](#tab1){ref-type="table"}). However significant differences in both nuclear and cytoplasmic IL-1*α* expression cores were observed based on smoking history, tumor site, T stage, N stage (cytoplasmic only), differentiation, perineural and lymphovascular invasion (cytoplasmic only), bone invasion, and the number of patients that received radiotherapy or chemotherapy ([Table 1](#tab1){ref-type="table"}). There were not enough HPV-positive tumors to assess differences in IL-1*α* expression. Since the IL-1*α* expression profiles 1/1, 2/1, and 1/0 represented the majority of tumors in the TMA ([Table 2](#tab2){ref-type="table"}), we further analyzed the association of these expression profiles with clinicopathological features of the represented OSCC patients. We found no differences in overall survival (*p*=0.27) or progression-free survival (*p*=0.29) with respect to these 3 major IL-1*α* expression profiles (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}).

3.4. EGFR Expression {#sec3.4}
--------------------

We next examined the role of EGFR expression in survival outcomes in OSCC patients. Examples of EGFR expression scores are shown in [Figure 3](#fig3){ref-type="fig"}. EGFR expression was observed in 61% of the tumors with strong (score of 3) expression in 34%, moderate (score of 2) expression in 16%, low (score of 1) expression in 11%, and no (score of 0) expression in of 39% of tumors ([Table 3](#tab3){ref-type="table"}). There were no differences observed in overall survival (*p*=0.69) according to EGFR scores ([Figure 4(a)](#fig4){ref-type="fig"}); however significant differences were observed in progression-free survival (*p*=0.04) with higher EGFR expression being associated with worse progression-free survival ([Figure 4(b)](#fig4){ref-type="fig"}). A comparison of combined strong (3)+moderate (2) EGFR (designated as EGFR+) expression and combined low (1)+no (0) EGFR (designated as EGFR-) expression also showed a significant difference in progression-free survival (*p*=0.02) ([Figure 4(d)](#fig4){ref-type="fig"}) but not overall survival (*p*=0.22) ([Figure 4(c)](#fig4){ref-type="fig"}). These results support prior reports that EGFR expression is a strong predictor of progression-free survival in HNSCC patients \[[@B16], [@B22]\].

3.5. Correlation of Combined EGFR and IL-1*α* with Patient Outcomes {#sec3.5}
-------------------------------------------------------------------

We next evaluated if differences in nuclear/cytoplasmic IL-1*α* expression scores altered the predictive value of EGFR. There were no significant differences (*p*=0.31) in EGFR expression in tumors with 1/0, 1/1, and 2/1 IL-1*α* expression profiles ([Figure 5(a)](#fig5){ref-type="fig"}). Tumors with a high nuclear/moderate cytoplasmic IL-1*α* expression profile (2/1) combined with a moderate/strong (2/3) EGFR expression score, which was designated as 2/1/EGFR+, were significantly (*p*=0.0058) more likely to experience tumor recurrence compared to the other IL-1*α*/EGFR expression profiles ([Figure 5(b)](#fig5){ref-type="fig"}). We also found a significant interaction (p=0.02) between the 2/1 IL-1*α* profile score and EGFR+ expression ([Figure 5(b)](#fig5){ref-type="fig"}) suggesting that this particular 2/1/EGFR+ expression profile could be considered a predictor of tumor recurrence. The high rates of recurrences observed in 2/1/EGFR+ tumors encompassed local, regional, and distant sites alone and in combination ([Figure 5(c)](#fig5){ref-type="fig"}). Additionally, 2/1/EGFR+ tumors displayed significantly higher rates of perineural invasion (p\<0.0001) compared to the other IL-1*α*/EGFR expression profiles ([Figure 6(a)](#fig6){ref-type="fig"}). There were no differences among the IL-1*α*/EGFR expression profiles with respect to lymphovascular invasion ([Figure 6(b)](#fig6){ref-type="fig"}) and bone invasion ([Figure 6(c)](#fig6){ref-type="fig"}).

Lastly, we found that patients with 2/1/EGFR+ tumors trended toward worse overall survival compared to 2/1/EGFR- tumors although this association did not reach statistically significance (*p*=0.06) ([Figure 7(a)](#fig7){ref-type="fig"}). However, 2/1/EGFR+ tumors were significantly associated with worse progression-free survival compared to 2/1/EGFR- tumors (*p*\<0.0001) ([Figure 7(b)](#fig7){ref-type="fig"}). EGFR expression did not affect survival outcomes in 1/1 (Figures [7(c)](#fig7){ref-type="fig"} and [7(d)](#fig7){ref-type="fig"}) or 1/0 tumors (Figures [7(e)](#fig7){ref-type="fig"} and [7(f)](#fig7){ref-type="fig"}). Compared to patients with an overall EGFR- expression profile (median survival = 61.4 months, [Figure 4(d)](#fig4){ref-type="fig"}), patients specifically with 2/1/EGFR- tumors appeared to have the most favorable progression-free survival outcome (median survival=not reached) out of all of the other profiles ([Figure 7(b)](#fig7){ref-type="fig"}). Furthermore, we confirmed in [Table 4](#tab4){ref-type="table"} that adjuvant chemotherapy and/or radiation treatment did not influence the differences in progression-free survival observed with 2/1/EGFR+ versus 2/1/EGFR- tumors ([Figure 7(b)](#fig7){ref-type="fig"}). Altogether, these data suggest that high nuclear IL-1*α* expression in combination with moderate/high EGFR expression may be associated with worse outcomes in OSCC patients.

4. Discussion {#sec4}
=============

The results from this study imply that nuclear IL-1*α* expression may enhance the prognostic value of EGFR with respect to progression-free survival. EGFR is already well known as a prognostic indicator in HNSCCs; therefore the question remains of what role does nuclear IL-1*α* play in EGFR signaling? IL-1*α* has been reported to be associated with poor prognosis in a wide range of cancers \[[@B7], [@B23]--[@B26]\]. In HNSCCs, gene expression, tumor cell secretion, and circulating levels of IL-1*α* have all been associated with tumor progression and distant metastasis \[[@B5]--[@B7]\]. On the other hand IL-1*α* is involved in antitumor immunity via increased natural killer (NK) cell activity, dendritic cell activity, and enhanced Th1-mediated immunity \[[@B9], [@B27]--[@B29]\]. These 2 opposing properties create a controversy surrounding the potential long-term clinical effectiveness of IL-1 inhibitors for cancer therapy. The additional presence of nuclear IL-1*α* further complicates this field since the activity of nuclear IL-1*α* is independent of the IL-1R1. For these reasons, little/no attention has been placed on the*in situ* analysis of IL-1*α* protein expression and the prognostic implications of IL-1*α* subcellular location.

In this study we have found that IL-1*α* is expressed in the vast majority of OSCC tumors and that IL-1*α* is expressed in both the nuclear and cytoplasmic components ([Figure 1](#fig1){ref-type="fig"}). We observed predominant nuclear expression of IL-1*α* since most of the IL-1*α* expressing tumors had either nuclear only or nuclear+cytoplasmic expression ([Table 2](#tab2){ref-type="table"}). Only 4 tumors had cytoplasmic only staining highlighting the importance of nuclear IL-1*α* (i.e., pro-IL-1*α* and/or IL-1*α* propiece (ppIL-1*α*)) in tumor cells. In support of this observation, prior studies have also shown that pro-IL-1*α* and ppIL-1*α* appear to be predominantly intranuclear in IL-1*α*-expressing or IL-1*α*-transfected cells \[[@B30]--[@B33]\]. Based on the particular IL-1*α* antibody (ab9614, Abcam) used in these studies, the nuclear IL-1*α* detected is likely pro-IL-1*α* and not ppIL-1*α*. To date it is not clear what role nuclear IL-1*α* plays since some studies have reported that nuclear IL-1*α* inhibits cell proliferation \[[@B30], [@B31]\] and triggers apoptosis \[[@B32]\]; and in other studies nuclear IL-1*α* promotes cell proliferation \[[@B34]\]. It is possible that differences in experimental techniques and cell models may explain these contradicting reports. Nevertheless, we find no prognostic value in IL-1*α* subcellular localization (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}) in this cohort of OSCC patients. However, when we take into consideration EGFR expression we found unexpected but interesting results. When separating patients from the 2/1, 1/1, and 1/0 IL-1*α*-expressing groups into EGFR+ and EGFR- subgroups, we uncover a subset of tumors with a 2/1/EGFR+ profile that demonstrates significantly increased rates of perineural invasion compared to all other IL-1*α*/EGFR expression profiles ([Figure 6(a)](#fig6){ref-type="fig"}). The presence of perineural invasion is a strong and independent predictor of local and regional failure in OSCC patients \[[@B35]--[@B38]\]. Therefore it is no surprise that patients bearing tumors with this 2/1/EGFR+ expression profile were significantly more likely to recur compared to all of the other IL-1*α*/EGFR expression profiles ([Figure 5(b)](#fig5){ref-type="fig"}). Patients with 2/1/EGFR+ tumors also demonstrated worse progression-free survival compared to 2/1/EGFR- tumors (Figures [7(a)](#fig7){ref-type="fig"} and [7(b)](#fig7){ref-type="fig"}). This difference with EGFR expression was not observed in 1/1 (Figures [7(c)](#fig7){ref-type="fig"} and [7(d)](#fig7){ref-type="fig"}) or 1/0 (Figures [7(e)](#fig7){ref-type="fig"} and [7(f)](#fig7){ref-type="fig"}) tumors suggesting a possible interaction between high nuclear IL-1*α* activity and EGFR signaling which is supported by the significant interaction (*p*=0.02) found in [Figure 5(b)](#fig5){ref-type="fig"} between the 2/1 IL-1*α* profile score and EGFR+ expression. Of note, we found that 61% of OSCC patients with EGFR+ (score of 2 and 3) tumors experienced tumor recurrence with a median progression-free survival of 13 months ([Figure 4(d)](#fig4){ref-type="fig"}). However, if only patients with 2/1/EGFR+ tumors are taken into account, 94% of these patients experienced tumor recurrence with a median survival of 7 months ([Figure 7(b)](#fig7){ref-type="fig"}). This suggests that 2/1/EGFR-positivity may be a stronger and more accurate indicator of recurrence and progression-free survival than EGFR expression alone.

At this time, we are unclear as to the role of nuclear IL-1*α* activity in EGFR signaling. Prior reports have shown that nuclear IL-1*α* is involved in transcriptional control by interacting with the histone acetyltransferases p300, PCAF, and Gcn5 \[[@B39]--[@B41]\]. Transcription factors important in cancer and proinflammation pathways such as NFkB, Elk-1, C/EBP*β*, or AP-1 are activated by both IL-1 ligands and EGF \[[@B42]\]. EGFR activation has been shown to increase IL-1 ligand expression via increased NFkB activity in breast cancer cells resulting in increased growth and invasion \[[@B43]\]. Also, IL-1 ligands have been reported to transactivate EGFR through a CXCL1-CXCR2 axis \[[@B17]\] and ADAM17 \[[@B18]\] suggesting crosstalk between the EGFR and IL-1 pathways. These reports all support the synergistic interaction between the EGFR and IL-1 pathways but does not fully explain the preferential interaction of EGFR expression with nuclear IL-1*α*. Recently nuclear IL-1*α* has been shown to increase cell proliferation in T-lymphocytic leukemia cells by binding to the promoter region of sp1 leading to increased sp1 expression and activity \[[@B15]\]. Sp1 is a transcription factor involved in cell growth, immune responses, and chromatin remodeling \[[@B44]\]. Sp1 is also involved in the regulation of numerous genes involved in invasion and metastasis \[[@B45]--[@B47]\]. EGFR promoter activation requires sp1 and multiple binding sites for sp1 have been discovered \[[@B48]--[@B50]\]. This suggests that high nuclear IL-1*α* expression may promote EGFR signaling via sp1 activity which would explain the high recurrence rates observed in patients with 2/1/EGFR+ tumors ([Figure 5(b)](#fig5){ref-type="fig"}). Moreover, the IL-1*α* gene has been reported to be regulated by sp1 \[[@B51], [@B52]\] suggesting a feed-forward relationship between IL-1*α* and sp1 which would ultimately promote EGFR signaling and tumor progression. Further mechanistic studies in this area are necessary to investigate this theory.

5. Conclusions {#sec5}
==============

Altogether, we believe we have identified a combined high nuclear IL-1*α*/EGFR+ tumor expression profile as a strong prognostic biomarker for progression-free survival in OSCC patients which warrants further study in other HNSCCs and other EGFR-expressing tumors.
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![Representative examples of nuclear and cytoplasmic IL-1*α* immunostaining in OSCC and expression scores. (a) IL-1*α* expression in the nuclei; (b) IL-1*α* expression in the cytoplasm; and (c) IL-1*α* in both the nuclei and cytoplasm. (d) negative nuclear and cytoplasmic IL-1*α* expression; (e) moderate nuclear and negative cytoplasmic IL-1*α* expression; (f) negative nuclear and moderate cytoplasmic IL-1*α* expression; (g) moderate nuclear and cytoplasmic IL-1*α* expression; (h) moderate nuclear and strong cytoplasmic IL-1*α* expression; (i) strong nuclear and moderate cytoplasmic IL-1*α* expression. N: nuclear; C: cytoplasmic.](JO2019-5859680.001){#fig1}

![Prognostic impact by IL-1*α* expression score. Shown are Kaplan-Meier estimates of overall survival (a) and disease-free survival (b) according to IL-1*α* expression score.](JO2019-5859680.002){#fig2}

![Representative examples of EGFR immunostaining and expression scores in OSCCs.](JO2019-5859680.003){#fig3}

![Prognostic impact by EGFR expression score. Shown are Kaplan-Meier estimates of overall survival (a, c) and disease-free survival (b, d) according to EGFR expression score. EGFR+ and EGFR- in (c) and (d) represent combined EGFR (3) + EGFR (2) and EGFR (1) + EGFR (0) scores, respectively. NR: not reached.](JO2019-5859680.004){#fig4}

![Recurrence rates by combined EGFR/IL-1*α* scores. Shown are the percentage of tumors (a) and percentage of tumor recurrences (b) based on combined EGFR and IL-1*α* expression scores. Location of recurrences in 2/1/EGFR+ tumors are shown in (c).](JO2019-5859680.005){#fig5}

![Invasion rates by combined EGFR/IL-1*α* scores. Shown are the percentages of tumors with perineural invasion (a), lymphovascular invasion (b), and bone invasion (c) by combined EGFR and IL-1*α* expression scores.](JO2019-5859680.006){#fig6}

![Prognostic impact by combined EGFR/IL-1*α* expression scores. Shown are Kaplan-Meier estimates of overall survival (a,c,e) and progression-free survival (b,d,f) according to EGFR expression scores and 2/1 (a,b), 1/1 (c,d) and 1/0 (e,f) IL-1*α* scores. HR: hazard ratio, CI: 95% confidence interval. NR: not reached.](JO2019-5859680.007){#fig7}

###### 

Patient characteristics by IL-1*α* Immunostaining.

                                      Nuclear IL-1*α∗*             Cytoplasmic IL-1*α∗*                                       
  ------------------------- --------- ------------------ --------- ---------------------- ---------- --------- --------- ---- -----------
  Number of Evaluable       141                                                                                                
  Subjects                                                                                                                    
  Sex                                                                                                                          
   Male                     82        57                 58        57                     0.99       50        58        59   0.37
   Female                   59        43                 42        43                     50         42        41             
  Avg Age at Diagnosis                                                                                                        
   Male                     58        59                 58        54                     0.74       53        57        62   0.28
   (avg (range))            (31-81)   (37-76)            (31-81)   (44-69)                           (31-81)   (37-73)        
   Female                   66        58                 68        63                     78         67        61             
   (avg (range))            (19-33)   (19-81)            (20-93)   (58-73)                           (19-93)   (44-80)        
  Smoking History                                                                                                              
   Active Smoker            56        36                 42        29                     \<0.0001   0         39        44   \<0.0001
   Never Smoker             49        29                 38        14                     100        34        33             
   Quit \<10 Years          13        14                 7         29                     0          9         11             
   Quit \>10 Years          17        11                 11        29                     0          13        11             
   Tobacco Chewer           6         11                 3         0                      0          5         0              
  Tumor Site                                                                                                                   
   Alveolus                 21        7                  18        0                      \<0.0001   50        13        19   \<0.0001
   Floor of the Mouth       31        18                 23        29                     0          17        44             
   Oral Tongue              54        46                 37        29                     0          44        19             
   Other                    35        29                 23        43                     50         26        19             
  T Stage                                                                                                                      
   T1                       42        36                 29        14                     0.001      50        30        26   \<0.00001
   T2                       42        36                 28        29                     0          30        30             
   T3/T4                    57        29                 42        57                     50         39        44             
  N Stage                                                                                                                      
   N0                       74        43                 56        43                     0.137      50        54        48   \<0.00001
   N1/2a                    27        29                 16        29                     0          16        33             
   N2b/2c/3                 40        29                 28        29                     50         30        19             
  Differentiation                                                                                                              
   well                     17        7                  13        14                     \<0.001    0         13        7    \<0.0001
   moderate                 90        75                 62        43                     50         64        63             
   poor                     34        18                 25        43                     50         22        30             
  Perineural Invasion                                                                                                         
   Yes                      69        61                 45        57                     0.06       0         50        48   \<0.001
   No                       72        39                 55        43                     100        50        52             
  Lymphovascular Invasion                                                                                                     
   Yes                      52        43                 35        43                     0.41       50        39        26   0.002
   No                       89        57                 65        57                     50         61        74             
  Bone Invasion                                                                                                                
   Yes                      42        21                 68        29                     \<0.001    50        29        30   0.002
   No                       99        79                 32        71                     50         71        70             
  Radiotherapy                                                                                                                 
   Yes                      78        57                 54        71                     0.032      100       53        63   \<0.00001
   No                       63        43                 46        29                     0          47        37             
  Chemotherapy                                                                                                                 
   Yes                      22        14                 15        29                     0.011      50        15        15   \<0.00001
   No                       119       86                 85        71                     50         85        85             

*∗*Percentages may not sum to 100% due to rounding.

###### 

IL-1*α* expression scores in HNSCC tumors.

  IL-1*α* Expression Scores*∗*   Number of Tumors
  ------------------------------ ------------------
  0/0                            3 (2.1)
  0/1                            4 (2.8)
  1/0                            23 (16.3)
  1/1                            81 (57.5)
  1/2                            2 (1.4)
  2/0                            1 (0.7)
  2/1                            27 (19.2)

*∗*0: negative; 1: moderate; 2: strong

###### 

EGFR expression scores in OSCC tumors.

  -----------------------------------------------------------------
  EGFR\                 Number\         Number of Recurrences (%)
  Expression Score*∗*   of Tumors (%)   
  --------------------- --------------- ---------------------------
  0                     55 (39)         26 (47)

  1                     15 (11)         6 (40)

  2                     23 (16)         12 (52)

  3                     48 (34)         31 (65)
  -----------------------------------------------------------------

*∗*0: negative; 1: low; 2: moderate; 3: strong

###### 

Postsurgery therapy in OSCC patients.

  ------------------------------------------------------------------------------------------------------
  EGFR*∗*/IL-1*α*\     Number\       Chemotherapy (%)   Radiation\   Chemotherapy+Radiation\   P-value
  Expression Profile   of Patients                      (%)          (%)                       
  -------------------- ------------- ------------------ ------------ ------------------------- ---------
  2/1/EGFR+            *16*          *3 (19)*           *10 (63)*    *3 (19)*                  *0.19*

  2/1/EGFR-            *11*          *1 (9)*            *6 (55)*     *1 (9)*                   

  1/1/EGFR+            *39*          *7 (18)*           *17 (44)*    *7 (18)*                  *0.10*

  1/1/EGFR-            *42*          *5 (12)*           *24 (57)*    *5 (12)*                  

  1/0/EGFR+            *8*           *0 (0)*            *4 (50)*     *0 (0)*                   *0.008*

  1/0/EGFR-            *15*          *2 (13)*           *10 (67)*    *2 (13)*                  
  ------------------------------------------------------------------------------------------------------

*∗*EGFR+: strong (3)+moderate (2) expression

EGFR-: low (1)+negative (0) expression

[^1]: Academic Editor: Shinji Miwa
